Skip to main content

AS/Spondyloarthritis

      RT @RHEUMarampa: SKIPPAIN trial: SEC showed rapid and significant improvement of spinal pain (primary endpt) and ⬇ dis
      4 years ago
      SKIPPAIN trial: SEC showed rapid and significant improvement of spinal pain (primary endpt) and ⬇ disease activity in axSpA @RheumNow #ACR20 abs0899 #ACRbest https://t.co/fKSEjwd6i9
      RT @uptoTate: Do you consistently address T2T in your axSpA patients in your clinical practice? List your measures below
      Do you consistently address T2T in your axSpA patients in your clinical practice? List your measures below! #ACR20 @RheumNow
      RT @uptoTate: T2T in clinical practice: Most axSpA pts had ≥1 annual ASDAS recorded, but target ID/LDA achieved in onl
      T2T in clinical practice: Most axSpA pts had ≥1 annual ASDAS recorded, but target ID/LDA achieved in only 1/3 of pts at the first measurement. How do you address T2T in your practice? #ABS0879 #ACR20 @RheumNow https://t.co/Jy0mmqpHAb https://t.co/06fI10V3OZ
      RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by Novartis. All content chosen by @Rhe
      4 years ago
      RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by Novartis. All content chosen by @RheumNow and its Faculty.
      RT @uptoTate: Baseline characteristics differed between M/F pts w/ AS & nr-axSpA. Women were older at dz onset w/lon
      Baseline characteristics differed between M/F pts w/ AS & nr-axSpA. Women were older at dz onset w/longer symptom duration & more joint dz and were less likely to be + HLA-B27 than men. Do you see this in your practice? #ABS0876 #ACR20 @RheumNow https://t.co/2goek1NiUW https://t.co/Uk8pmNP4Hr
      RT @RHEUMarampa: Pooled analysis from MEASURE 1-5 showed SEC was effective for AS regardless of HLA-B27 status. HLA-B27+
      4 years ago
      Pooled analysis from MEASURE 1-5 showed SEC was effective for AS regardless of HLA-B27 status. HLA-B27+ pts had more therapeutic benefit vs. HLA-B27- pts. @RheumNow #ACR20 abs#0885 #ACRbest https://t.co/eD3ZGWxDkX
      Psoriatic Disease: Dr. Lianne Gensler

       

      Dr. Lianne Gensler reviews Abstracts #0504, #0505, #0506, #0507 regarding psoriatic arthritis presented Friday at the ACR 2020 annual meeting.

      RT @synovialjoints: New treatments in Axial Spa at #ACR20. A significantly higher proportion of pts receiving Upadactini
      New treatments in Axial Spa at #ACR20. A significantly higher proportion of pts receiving Upadactinib vs placebo achieved reductions in all PGA of pain assessments and sustained to week 64 @RheumNow Abstr#369
      RT @synovialjoints: Secukinumab has been used to treat spinal involvement in axial SpA. Secukinumab led to significant i

      Secukinumab has been used to treat spinal involvement in axial SpA. Secukinumab led to significant improvements in symptoms of peripheral arthritis in pts with AS. Significant improvements were seen in both tender and swollen joints @RheumNow #ACR20 Abstr#366